China Biopharma Inc. to Introduce an Immunotherapeutic Vaccine into China
PRINCETON, N.J., June 26 /PRNewswire-FirstCall/ -- China Biopharma, Inc. has reached a tentative agreement with Delmont Laboratory to introduce its immunotherapeutic vaccine Staphage Lysate that treats diseases of staphylococcal infection. According to this initial agreement, Delmont Laboratory will supply bulk materials and China Biopharma will contract local manufactures for the final packaging in China. CBPC will also conduct a study before a definitive agreement is to be signed. This product requires a clinical study and an approval from the Chinese SFDA before it is sold in China, though the product already has the FDA approval.
As many as 1.2 million U.S. hospital patients may be infected each year with a Staph infection which is resistant to antibiotics, according to a research conducted by Association for Professional in Infection Control and Epidemiology. Each year up to 119,000 of these patients may die from the tough-to-treat strain of bacterium, called methicillin-resistant Staphylococcus aureus (MRSA). No effective drugs are currently available in China to treat this infection and this vaccine is greatly needed.
The approval process may take about two years and once approved it would bring up to $20-30 million sales revenue every year.
About China Biopharma, Inc.
China Biopharma Inc. is a fast-growing biopharmaceutical company based in China. Through its operating subsidiaries, the company develops and distributes biopharmaceutical and pharmaceutical products throughout the world's most populated country, China. Products include human vaccines and other pharmaceutical drugs. Leveraging its investment and ownership of local Chinese biopharmaceutical companies, and partnerships with international biopharmaceutical companies, China Biopharma is building a highly-competitive platform for growth in China as well as new world markets, including the U.S. and Europe. For more information, visit its website at http://www.chinabiopharma.net.
CONTACT: China Biopharma, Inc. Attn.: George Ji Tel: +1 (609) 651-8588 ir@chinabiopharma.nethttp://www.chinabiopharma.net
Safe Harbor Statement
Some of the statements here discuss future events and developments, including the Company's future business strategy and its ability to generate revenue, income and cash flow, and should be considered forward-looking statements within the meaning of the Private Securities Litigation Reform Act of 1995. These "forward-looking" statements can generally be identified by words such as "expect," "anticipate," "believe," "estimate," "intend," "plan," and similar expressions. These statements involve a high degree of risk and uncertainty that exists in the Company's operations and business environment and are subject to change based on various factors that could cause actual Company results, performance, plans, goals and objectives to differ materially from those contemplated or implied in these forward-looking statements. Actual results may be different from anticipated results for a number of reasons, including the Company's new and uncertain business model, uncertainty regarding acceptance of the Company's products and services and the Company's limited operating history.
China Biopharma, Inc.
CONTACT: China Biopharma, Inc., George Ji, +1-609-651-8588,ir@chinabiopharma.net
Web site: http://www.chinabiopharma.net/